Editorial: Homocysteine lowering in end-stage renal disease: Is there any cardiovascular benefit?

Circulation

Volumn 121, Issue 12, 2010, Pages 1379-1381

  De Koning, Lawrence ^a   Hu, Frank B ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CHANNING LABORATORY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; VITAMIN B GROUP;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIALYSIS; DISEASE ASSOCIATION; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; GLOMERULUS FILTRATION RATE; HETEROZYGOTE; HOMOCYSTINURIA; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECT; NOTE;

CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 77950287119     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e3181daa7c9     Document Type: Editorial

References (27)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
3. Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2010;64:208-215.
4. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296:2720-2726.
5. Potter K, Hankey GJ, Green DJ, Eikelboom JW, Arnolda LF. Homo-cysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol. 2008;28:1158-1164.
6. Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate: a meta-analysis of 41 studies with 27,000 participants. Kidney Blood Press Res. 2008;31:259-267.
7. De Koning ABL, Werstuck GH, Zhou J, Austin RC. Hyperhomocys-teinemia and its role in the development of atherosclerosis. Clin Biochem. 2003;36:431-441.
8. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. Biofactors. 2009; 35:120-129.
9. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocys-teinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-683.
10. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with homo-cystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost. 2000;26: 335-340.
11. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. Vascular outcome in patients with homo-cystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21:2080-2085.
12. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
13. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C[rarr]T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031
14. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151:282-287
15. Homocysteine Lowering Trialists' Collaboration. Lowering blood homo-cysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998;316:894-898.
16. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
17. Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331-340.
18. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl): S16-S23.
19. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis. 2009;54:478-489.
20. Righetti M. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clin Chem Lab Med. 2007; 45:1586-1589.
21. Heinz J, Kropf S, Domröse U, Westphal S, Borucki K, Luley C, Neumann KH, Dierkes J. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation. 2010;112:1432-1438.
22. Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis. 2009;53: 121-128.
23. What is homocysteine? American Heart Association. http://www. americanheart.org/presenter.jhtml?identifier = 535. Accessed February 18, 2010.
24. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009;169:659-669.
25. Tsai MY, Loria CM, Cao J, Kim Y, Siscovick D, Schreiner PJ, Hanson NQ. Clinical utility of genotyping the 677C[rarr]T variant of methylene- tetrahydrofolate reductase in humans is decreased in the post-folic acid fortification era. J Nutr. 2009;139:33-37.
26. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, Saito M, Kikuchi S, Noguchi Y, Sugishita Y, Hamaguchi H. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis. 1998;137:23-28.
27. Tanis BC, Blom HJ, Bloemenkamp DG, van den Bosch MA, Algra A, van der Graaf Y, Rosendaal FR. Folate, homocysteine levels, methylene-tetrahydrofolate reductase (MTHFR) 677C[rarr]T variant, and the risk of myocardial infarction in young women: effect of female hormones on homocysteine levels. J Thromb Haemost. 2004;2:35-41